Back

Clinical and prognosis assessment of Atrial Fibrillation patients with significant valvular disease. Validation of the EHRA valve classification (Evaluated Heartvalves. Rheumatic or Artificial)

29 August 2022 (10:15 - 11:00)
Organised by:
Congress Presentation Part of: Rhythm and valvular heart disease Clinical ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Antonio Escolar Conesa

Virgen de la Arrixaca University Clinical Hospital, El Palmar (Spain)

6 More presentations in this session

Presentation thumbnail
Predictors of ventricular arrhythmias in arrhythmic mitral valve syndrome - a study using implantable loop recorders
Doctor E. Aabel (Oslo, NO)
Abstract Slides
Presentation thumbnail
Impact of atrial fibrillation in clinical outcomes of low gradient aortic stenosis
Doctor N. Kolluri (Rochester, US)
Abstract Slides
Presentation thumbnail
Ventricular arrhythmias and sudden cardiac death caused by mitral valve prolapse: should we operate and when?
Doctor J. Cameron (Melbourne, AU)
Abstract Slides
Presentation thumbnail
The impact of right atrium and left atrium reverse remodeling for functional regurgitation of atrioventricular valve among patients who were underwent ablation for atrial fibrillation
Doctor N. Nemoto (Ota-Shi, JP)
Abstract Slides
Presentation thumbnail
Exercise-induced ventricular arrythmia in asymptomatic patients with Mitral Valve Prolapse
Doctor T. Wallet (Paris, FR)
Abstract Slides

Access the full session

Session thumbnail
Rhythm and valvular heart disease

The Event

Event poster

ESC Congress 2022

29 August 2022 10:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources